Standout Papers

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Meta... 2006 2026 2012 2019 789
  1. Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma (2006)
    Mark J. Ratain, Tim Eisen et al. Journal of Clinical Oncology

Immediate Impact

14 by Nobel laureates 9 from Science/Nature 62 standout
Sub-graph 1 of 23

Citing Papers

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis
2022 Standout
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
2022 Standout

Works of Gary L. Rosner being referenced

Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology
2018
Quantifying over-estimation in early stopped clinical trials and the “freezing effect” on subsequent research
2016

Author Peers

Author Last Decade Papers Cites
Gary L. Rosner 2947 1263 2848 1525 203 8.9k
Hajime Uno 1919 970 1000 1230 185 8.2k
Ram C. Tiwari 4046 1460 2539 2768 219 11.6k
Peter F. Thall 2807 4317 2279 2504 333 13.8k
Stephen L. George 2297 799 1483 1491 169 9.0k
Edmund A. Gehan 3162 726 1787 4095 142 10.0k
Gary Longton 1638 362 1236 1269 87 6.9k
Sin‐Ho Jung 2622 1160 1506 1801 294 7.8k
Ruth Etzioni 7683 799 2668 7620 243 17.7k
Nancy L. Geller 2031 1036 1354 1596 218 11.3k
Michael LeBlanc 4540 884 1475 2189 259 11.2k

All Works

Loading papers...

Rankless by CCL
2026